)
Dannielle Appelhans, MBA
President and CEO
COUR Pharma
Dannielle Appelhans is the President and Chief Executive Officer of COUR Pharma. She joined COUR in 2023 as Chief Operating Officer and became CEO in 2024. Since joining, she has focused on maturing the company to take on late-stage clinical development of autoimmune disease treatments that utilize COUR’s platform technology for antigen-specific immune tolerance. Prior to joining COUR, Dannielle served in executive leadership positions at Rubius Therapeutics and Novartis. Earlier in her career, she held roles of increasing responsibility at McKinsey and Eli Lilly. Since 2022, Dannielle has served on the Board of Directors for Generation Bio. Dannielle earned a Master of Science in mechanical engineering from MIT’s School of Engineering, an MBA from MIT’s Sloan School of Management, and a Bachelor of Science in mechanical engineering from the University of Michigan.
Sessions
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}